Antitumor effects of a combined 5-aza-2′deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice

Ines Ecke, Frauke Petry, Albert Rosenberger, Svantje Tauber, Sven Mönkemeyer, Ina Hess, Christian Dullin, Sarah Kimmina, Judith Pirngruber, Steven Johnsen, Anja Uhmann, Frauke Nitzki, Leszek Wojnowski, Walter Schulz-Schaeffer, Olaf Witt, Heidi Hahn

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Patched (Ptch) heterozygous mice develop medulloblastoma (MB) and rhabdomyosarcoma (RMS) resembling the corresponding human tumors. We have previously shown that epigenetic silencing of the intact Ptch allele contributes to tumor formation in this model. Here,we investigated whether targeting of epigenetic silencing mechanisms could be useful in the treatment of Ptch-associated cancers. A reduction of endogenous DNA methyltransferase1 (Dnmt1) activity significantly reduced tumor incidence in heterozygous Ptch knockout mice. A combined treatment with the Dnmt inhibitor 5-aza- 2′deoxycytidine (5-aza-dC) and the histone deacetlyase (HDAC) inhibitor valproic acid (VPA) efficiently prevented MB and RMS formation, whereas monotherapies with either drug were less effective. Wild-type Ptch expression was efficiently reactivated in tumors by 5-aza-dC/VPA combination therapy. This was associated with reduced methylation of the Ptch promoter and induction of histone hyperacetylation suggesting inhibition of HDACs in vivo. However, the treatment was not effective in clinically overt, advanced stage tumors. This is a first in vivo demonstration that targeting of Dnmt and HDAC activities is highly effective in preventing formation of Ptch-associated tumors. The results suggest a novel clinical strategy for consolidation therapy of corresponding tumors in humans after completion of conventional treatment. Our data also suggest that epigenetic therapy may be less effective in treating advanced stages of tumors, at least in this tumor model.

Original languageEnglish (US)
Pages (from-to)887-895
Number of pages9
JournalCancer Research
Volume69
Issue number3
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

Medulloblastoma
Rhabdomyosarcoma
Valproic Acid
Neoplasms
Epigenomics
Histones
Second Primary Neoplasms
Knockout Mice
Methylation
Therapeutics
Alleles
DNA
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Antitumor effects of a combined 5-aza-2′deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. / Ecke, Ines; Petry, Frauke; Rosenberger, Albert; Tauber, Svantje; Mönkemeyer, Sven; Hess, Ina; Dullin, Christian; Kimmina, Sarah; Pirngruber, Judith; Johnsen, Steven; Uhmann, Anja; Nitzki, Frauke; Wojnowski, Leszek; Schulz-Schaeffer, Walter; Witt, Olaf; Hahn, Heidi.

In: Cancer Research, Vol. 69, No. 3, 01.02.2009, p. 887-895.

Research output: Contribution to journalArticle

Ecke, I, Petry, F, Rosenberger, A, Tauber, S, Mönkemeyer, S, Hess, I, Dullin, C, Kimmina, S, Pirngruber, J, Johnsen, S, Uhmann, A, Nitzki, F, Wojnowski, L, Schulz-Schaeffer, W, Witt, O & Hahn, H 2009, 'Antitumor effects of a combined 5-aza-2′deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice', Cancer Research, vol. 69, no. 3, pp. 887-895. https://doi.org/10.1158/0008-5472.CAN-08-0946
Ecke, Ines ; Petry, Frauke ; Rosenberger, Albert ; Tauber, Svantje ; Mönkemeyer, Sven ; Hess, Ina ; Dullin, Christian ; Kimmina, Sarah ; Pirngruber, Judith ; Johnsen, Steven ; Uhmann, Anja ; Nitzki, Frauke ; Wojnowski, Leszek ; Schulz-Schaeffer, Walter ; Witt, Olaf ; Hahn, Heidi. / Antitumor effects of a combined 5-aza-2′deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. In: Cancer Research. 2009 ; Vol. 69, No. 3. pp. 887-895.
@article{c9c359a9557b41ca9912f86c8cb13561,
title = "Antitumor effects of a combined 5-aza-2′deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice",
abstract = "Patched (Ptch) heterozygous mice develop medulloblastoma (MB) and rhabdomyosarcoma (RMS) resembling the corresponding human tumors. We have previously shown that epigenetic silencing of the intact Ptch allele contributes to tumor formation in this model. Here,we investigated whether targeting of epigenetic silencing mechanisms could be useful in the treatment of Ptch-associated cancers. A reduction of endogenous DNA methyltransferase1 (Dnmt1) activity significantly reduced tumor incidence in heterozygous Ptch knockout mice. A combined treatment with the Dnmt inhibitor 5-aza- 2′deoxycytidine (5-aza-dC) and the histone deacetlyase (HDAC) inhibitor valproic acid (VPA) efficiently prevented MB and RMS formation, whereas monotherapies with either drug were less effective. Wild-type Ptch expression was efficiently reactivated in tumors by 5-aza-dC/VPA combination therapy. This was associated with reduced methylation of the Ptch promoter and induction of histone hyperacetylation suggesting inhibition of HDACs in vivo. However, the treatment was not effective in clinically overt, advanced stage tumors. This is a first in vivo demonstration that targeting of Dnmt and HDAC activities is highly effective in preventing formation of Ptch-associated tumors. The results suggest a novel clinical strategy for consolidation therapy of corresponding tumors in humans after completion of conventional treatment. Our data also suggest that epigenetic therapy may be less effective in treating advanced stages of tumors, at least in this tumor model.",
author = "Ines Ecke and Frauke Petry and Albert Rosenberger and Svantje Tauber and Sven M{\"o}nkemeyer and Ina Hess and Christian Dullin and Sarah Kimmina and Judith Pirngruber and Steven Johnsen and Anja Uhmann and Frauke Nitzki and Leszek Wojnowski and Walter Schulz-Schaeffer and Olaf Witt and Heidi Hahn",
year = "2009",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-08-0946",
language = "English (US)",
volume = "69",
pages = "887--895",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Antitumor effects of a combined 5-aza-2′deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice

AU - Ecke, Ines

AU - Petry, Frauke

AU - Rosenberger, Albert

AU - Tauber, Svantje

AU - Mönkemeyer, Sven

AU - Hess, Ina

AU - Dullin, Christian

AU - Kimmina, Sarah

AU - Pirngruber, Judith

AU - Johnsen, Steven

AU - Uhmann, Anja

AU - Nitzki, Frauke

AU - Wojnowski, Leszek

AU - Schulz-Schaeffer, Walter

AU - Witt, Olaf

AU - Hahn, Heidi

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Patched (Ptch) heterozygous mice develop medulloblastoma (MB) and rhabdomyosarcoma (RMS) resembling the corresponding human tumors. We have previously shown that epigenetic silencing of the intact Ptch allele contributes to tumor formation in this model. Here,we investigated whether targeting of epigenetic silencing mechanisms could be useful in the treatment of Ptch-associated cancers. A reduction of endogenous DNA methyltransferase1 (Dnmt1) activity significantly reduced tumor incidence in heterozygous Ptch knockout mice. A combined treatment with the Dnmt inhibitor 5-aza- 2′deoxycytidine (5-aza-dC) and the histone deacetlyase (HDAC) inhibitor valproic acid (VPA) efficiently prevented MB and RMS formation, whereas monotherapies with either drug were less effective. Wild-type Ptch expression was efficiently reactivated in tumors by 5-aza-dC/VPA combination therapy. This was associated with reduced methylation of the Ptch promoter and induction of histone hyperacetylation suggesting inhibition of HDACs in vivo. However, the treatment was not effective in clinically overt, advanced stage tumors. This is a first in vivo demonstration that targeting of Dnmt and HDAC activities is highly effective in preventing formation of Ptch-associated tumors. The results suggest a novel clinical strategy for consolidation therapy of corresponding tumors in humans after completion of conventional treatment. Our data also suggest that epigenetic therapy may be less effective in treating advanced stages of tumors, at least in this tumor model.

AB - Patched (Ptch) heterozygous mice develop medulloblastoma (MB) and rhabdomyosarcoma (RMS) resembling the corresponding human tumors. We have previously shown that epigenetic silencing of the intact Ptch allele contributes to tumor formation in this model. Here,we investigated whether targeting of epigenetic silencing mechanisms could be useful in the treatment of Ptch-associated cancers. A reduction of endogenous DNA methyltransferase1 (Dnmt1) activity significantly reduced tumor incidence in heterozygous Ptch knockout mice. A combined treatment with the Dnmt inhibitor 5-aza- 2′deoxycytidine (5-aza-dC) and the histone deacetlyase (HDAC) inhibitor valproic acid (VPA) efficiently prevented MB and RMS formation, whereas monotherapies with either drug were less effective. Wild-type Ptch expression was efficiently reactivated in tumors by 5-aza-dC/VPA combination therapy. This was associated with reduced methylation of the Ptch promoter and induction of histone hyperacetylation suggesting inhibition of HDACs in vivo. However, the treatment was not effective in clinically overt, advanced stage tumors. This is a first in vivo demonstration that targeting of Dnmt and HDAC activities is highly effective in preventing formation of Ptch-associated tumors. The results suggest a novel clinical strategy for consolidation therapy of corresponding tumors in humans after completion of conventional treatment. Our data also suggest that epigenetic therapy may be less effective in treating advanced stages of tumors, at least in this tumor model.

UR - http://www.scopus.com/inward/record.url?scp=59149095188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149095188&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-0946

DO - 10.1158/0008-5472.CAN-08-0946

M3 - Article

C2 - 19155313

AN - SCOPUS:59149095188

VL - 69

SP - 887

EP - 895

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -